. Author manuscript; available in PMC: 2018 Jul 30.

Published in final edited form as: J Acquir Immune Defic Syndr. 2010 Sep;55(1):39–48. doi: 10.1097/QAI.0b013e3181da1287

TABLE 2.

Comparisons of Virologic and Immunologic Responses at Week 48 and Week 96

	%^* Patients (95% CI)^† With HIV RNA <50 Copies/mL		Change^‡ From Baseline CD4 cells/mm³ (95% CI)

	48-Week	96-Week	48-Week	96-Week
Raltegravir group	n = 280	n = 281	n = 280	n = 281
	86 (82 to 90)	81 (76 to 86)	189 (174 to 204)	240 (220 to 259)
Efavirenz group	n = 281	n = 282	n = 281	n = 282
	82 (77 to 86)	79 (74 to 83)	163 (148 to 178)	225 (206 to 244)
Difference between treatment groups^§	4^‖ (−2 to 10)	2^‖ (−4 to 9)	26 (4 to 47)	15 (−13 to 42)

The numbers differ at the 2 time points because data in 1 patient in each treatment arm was available at Week 96, but not at Week 48.

Missing data were handled by counting non-completers as failures.

^†

The 95% CI were calculated using the method of Miettinen and Nurminen.¹⁵

^‡

Missing data were handled by the observed-failure approach with baseline values carried forward for virologic failures.

^§

Difference was calculated as the value in the raltegravir group minus the value in the efavirenz.

^‖

The P value for noninferiority was <0.001.

n, number of patients.